STVN Stevanato Group SpA

Cooper Investors PTY Ltd. significantly increased its stake in Stevanato Group S.p.A. (NYSE:STVN) by 251.7% in the third quarter, making it their sixth-largest holding. Other institutional investors also raised their positions, reflecting growing interest in the pharmaceutical packaging provider. Despite mixed analyst ratings, with a consensus of "Moderate Buy," the company shows strong financial metrics and a substantial market capitalization.

Options traders are showing increased interest in Stevanato Group (STVN) stock, with high implied volatility in its Mar 20, 2026 $12.50 Call option suggesting expectations of a significant price movement. Despite this options activity, analysts currently rate Stevanato Group as a Zacks Rank #3 (Hold) in a strong industry, with recent downward revisions to earnings estimates. This divergence indicates potential trading opportunities for those who understand implied volatility and premium selling strategies.

Ranger Investment Management L.P. significantly increased its stake in Stevanato Group S.p.A. by 125.6% during the second quarter, acquiring 735,417 additional shares. This move made STVN the 12th largest position in Ranger Investment Management's holdings, valued at $32.27 million. Other institutional investors also boosted their holdings in Stevanato Group, indicating broader investor interest in the company.

Russell Investments Group Ltd. significantly increased its stake in Stevanato Group S.p.A. by 108.4% during Q2, now holding 191,103 shares valued at approximately $4.67 million. Other institutional investors like Champlain Investment Partners LLC and Artisan Partners Limited Partnership also boosted their holdings in the company. Stevanato Group, which trades on the NYSE, has a market capitalization of $6.66 billion and a "Moderate Buy" consensus rating from analysts.

Stevanato Group S.p.A.'s stock has declined despite seemingly decent financial indicators, particularly its Return on Equity (ROE) of 9.8%, which is comparable to the industry average. While the company has a low payout ratio suggesting strong reinvestment, its five-year net income growth of 3.6% is modest but still outperforms the industry average of 0.9%. Analysts expect an increase in the company's future ROE to 13%, suggesting potential for future earnings expansion despite a steady payout ratio.

Thornburg Investment Management Inc. significantly reduced its stake in Stevanato Group S.p.A. (NYSE:STVN) by 33.1% in the second quarter, selling 367,639 shares and retaining 742,245 shares valued at approximately $18.13 million. Despite this, analyst sentiment remains "Moderate Buy" with Morgan Stanley raising its price target to $26. Other institutional investors have recently adjusted their holdings in STVN as well, indicating varied investment strategies for the biopharmaceutical and healthcare solutions company.